Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MECAMYLAMINE HYDROCHLORIDE vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (n ACh Rs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
FDA: Management of moderately severe to severe essential hypertension and uncomplicated malignant hypertension.,Off-label: Treatment of Tourette syndrome, tics, and as an adjunct in smoking cessation.
Hypertension
Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life is approximately 12-24 hours; clinically, this allows once or twice daily dosing but requires dose adjustment in renal impairment.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Primarily hepatic with some renal excretion. Metabolized by cytochrome P450 enzymes, likely multiple isoforms, though specific enzymes not fully characterized.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal: 50-70% unchanged; biliary/fecal: minimal (less than 5%)
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Approximately 0-20% bound, primarily to albumin and alpha-1 acid glycoprotein; low binding is clinically insignificant.
Approximately 70-80% bound to plasma proteins, primarily albumin.
Vd approximately 1-2 L/kg; extensive tissue distribution indicates high penetration into tissues.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: approximately 20-50% due to incomplete absorption and first-pass metabolism.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Contraindicated in patients with renal insufficiency (e GFR <30 m L/min). For mild to moderate impairment, reduce dose by 50% and monitor closely.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose by 50% and titrate slowly.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not recommended for use in children due to lack of safety and efficacy data.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Initiate at 2.5 mg once daily; increase slowly with careful monitoring due to increased sensitivity to hypotensive effects and higher risk of adverse effects.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None.
None.
May cause orthostatic hypotension, syncope, and impaired mental alertness.,Caution in patients with poor renal function, prostatic hypertrophy, or pyloric stenosis.,Risk of rebound hypertension upon abrupt discontinuation.,Mecamylamine may precipitate urinary retention in patients with bladder dysfunction.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to mecamylamine or any component.,Coronary artery disease (risk of precipitation of angina).,Recent myocardial infarction.,Glaucoma (may increase intraocular pressure).,Uremia.,Concurrent use with ganglionic blocking agents.
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid excessive alcohol intake as it may potentiate hypotensive effects. No specific food restrictions beyond maintaining a balanced diet.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of teratogenicity due to ganglionic blockade; avoid unless essential. Second/third trimester: may cause fetal hypotension, hypoxia, meconium aspiration, and neonatal respiratory depression due to maternal hypotension and reduced uterine blood flow. Neonatal withdrawal syndrome reported with chronic use.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Excreted in breast milk; M/P ratio not established. Risk of infant ganglionic blockade (hypotension, constipation, urinary retention). Contraindicated in breastfeeding due to potential for serious adverse effects.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No established pregnancy-specific dose adjustments. Use lowest effective dose due to volume of distribution and clearance changes (increased plasma volume, renal clearance). Monitor closely for hypotension; consider dose reduction if significant maternal hypotension occurs.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Mecamylamine is a non-competitive antagonist of nicotinic acetylcholine receptors, used primarily for hypertension. It does not affect parasympathetic ganglia at therapeutic doses. Caution in patients with renal impairment as drug accumulation occurs. Avoid use in patients with glaucoma or pyloric stenosis due to anticholinergic effects.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed; do not skip doses or double up on missed doses.,Avoid driving or operating heavy machinery until you know how this medication affects you, as it can cause dizziness or blurred vision.,Report any signs of slow heart rate, fainting, difficulty urinating, or blurred vision to your healthcare provider immediately.,Do not stop taking this medication abruptly; your blood pressure may rise rapidly.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
"Mecamylamine, a noncompetitive nicotinic acetylcholine receptor antagonist used for hypertension, potentiates the vasodilatory effects of Manidipine, a dihydropyridine calcium channel blocker, by reducing sympathetic reflex responses that normally counteract calcium channel blocker-induced hypotension. This additive hypotensive effect can lead to severe hypotension, dizziness, syncope, and increased risk of falls or cardiovascular events, particularly in elderly patients or those with volume depletion."
"Mecamylamine, a noncompetitive antagonist of nicotinic acetylcholine receptors, blocks sympathetic ganglionic transmission, leading to reduced catecholamine release and hypotension. Phentolamine, a nonselective alpha-adrenergic antagonist, further inhibits vasoconstriction mediated by norepinephrine. Concurrent use results in additive hypotensive effects, increasing the risk of severe hypotension, orthostatic dizziness, and syncope, particularly during initial dosing or dose escalation."
"Mecamylamine, a ganglionic blocker, antagonizes nicotinic acetylcholine receptors, leading to sympatholytic effects. Nabilone, a synthetic cannabinoid, can increase heart rate via central sympathetic activation. The interaction results in Mecamylamine augmenting the tachycardic effects of Nabilone, potentially causing excessive heart rate elevation and risk of cardiac stress."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MECAMYLAMINE HYDROCHLORIDE vs ALDOCLOR-150, answered by our medical review team.
MECAMYLAMINE HYDROCHLORIDE is a Antihypertensive that works by Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (n ACh Rs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MECAMYLAMINE HYDROCHLORIDE and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MECAMYLAMINE HYDROCHLORIDE is: Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MECAMYLAMINE HYDROCHLORIDE and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MECAMYLAMINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of ter. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.